My lab aims to define critical proteins in cancer cells that can be targeted therapeutically. Because of the high cost of developing new therapies, it is essential that we first identify which alterations can be targeted productively. We are concentrating our efforts on using a genetic approach in tumors that are refractory to conventional therapies, including metastatic melanoma and glioblastoma. We plan to further validate these targets using pharmacological inhibitors of clinical importance.